Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery

Por Brown, James R, Auger, Kurt R
Publicado em 2011

Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors

Por Lai, Zhihong, Yang, Tao, Kim, Young B., Sielecki, Thais M., Diamond, Melody A., Strack, Peter, Rolfe, Mark, Caligiuri, Maureen, Benfield, Pamela A., Auger, Kurt R., Copeland, Robert A.
Publicado em 2002

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

Por Wyce, Anastasia, Ganji, Gopinath, Smitheman, Kimberly N., Chung, Chun-wa, Korenchuk, Susan, Bai, Yuchen, Barbash, Olena, Le, BaoChau, Craggs, Peter D., McCabe, Michael T., Kennedy-Wilson, Karen M., Sanchez, Lydia V., Gosmini, Romain L., Parr, Nigel, McHugh, Charles F., Dhanak, Dashyant, Prinjha, Rab K., Auger, Kurt R., Tummino, Peter J.
Publicado em 2013

Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT)

Por Yang, Hongfang, Medeiros, Patricia F., Raha, Kaushik, Elkins, Patricia, Lind, Kenneth E., Lehr, Ruth, Adams, Nicholas D., Burgess, Joelle L., Schmidt, Stanley J., Knight, Steven D., Auger, Kurt R., Schaber, Michael D., Franklin, G. Joseph, Ding, Yun, DeLorey, Jennifer L., Centrella, Paolo A., Mataruse, Sibongile, Skinner, Steven R., Clark, Matthew A., Cuozzo, John W., Evindar, Ghotas
Publicado no ACS Med Chem Lett (2015)

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Por Dawson, Mark A., Prinjha, Rab K., Dittman, Antje, Giotopoulos, George, Bantscheff, Marcus, Chan, Wai-In, Robson, Samuel C, Chung, Chun-wa, Hopf, Carsten, Savitski, Mikhail M., Huthmacher, Carola, Gudgin, Emma, Lugo, Dave, Beinke, Soren, Chapman, Trevor D., Roberts, Emma J., Soden, Peter E, Auger, Kurt R., Mirguet, Olivier, Doehner, Konstanze, Delwel, Ruud, Burnett, Alan K., Jeffrey, Phillip, Drewes, Gerard, Lee, Kevin, Huntly, Brian J.P, Kouzarides, Tony
Publicado em 2011

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Por Knight, Steven D., Adams, Nicholas D., Burgess, Joelle L., Chaudhari, Amita M., Darcy, Michael G., Donatelli, Carla A., Luengo, Juan I., Newlander, Ken A., Parrish, Cynthia A., Ridgers, Lance H., Sarpong, Martha A., Schmidt, Stanley J., Van Aller, Glenn S., Carson, Jeffrey D., Diamond, Melody A., Elkins, Patricia A., Gardiner, Christine M., Garver, Eric, Gilbert, Seth A., Gontarek, Richard R., Jackson, Jeffrey R., Kershner, Kevin L., Luo, Lusong, Raha, Kaushik, Sherk, Christian S., Sung, Chiu-Mei, Sutton, David, Tummino, Peter J., Wegrzyn, Ronald J., Auger, Kurt R., Dhanak, Dashyant
Publicado em 2010

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Por Qian, Xiangping, McDonald, Andrew, Zhou, Han-Jie, Adams, Nicholas D., Parrish, Cynthia A., Duffy, Kevin J., Fitch, Duke M., Tedesco, Rosanna, Ashcraft, Luke W., Yao, Bing, Jiang, Hong, Huang, Jennifer K., Marin, Melchor V., Aroyan, Carrie E., Wang, Jianchao, Ahmed, Seyed, Burgess, Joelle L., Chaudhari, Amita M., Donatelli, Carla A., Darcy, Michael G., Ridgers, Lance H., Newlander, Ken A., Schmidt, Stanley J., Chai, Deping, Colón, Mariela, Zimmerman, Michael N., Lad, Latesh, Sakowicz, Roman, Schauer, Stephen, Belmont, Lisa, Baliga, Ramesh, Pierce, Daniel W., Finer, Jeffrey T., Wang, Zhengping, Morgan, Bradley P., Morgans, David J., Auger, Kurt R., Sung, Chiu-Mei, Carson, Jeff D., Luo, Lusong, Hugger, Erin D., Copeland, Robert A., Sutton, David, Elliott, John D., Jackson, Jeffrey R., Wood, Kenneth W., Dhanak, Dashyant, Bergnes, Gustave, Knight, Steven D.
Publicado em 2010